Trial Profile
Vascular Targeted Photodynamic Therapy With WST11 for T1a Renal Tumours. PHASE IIa Histological Follow up Trial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Jul 2019
Price :
$35
*
At a glance
- Drugs Padeliporfin (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 12 Sep 2018 Results (n=313) from PCM201, PCM203 and PCM301 studies published in the Journal of Urology
- 08 Jan 2018 Status changed from recruiting to discontinued due to concerns about post VTP MRI results being conclusive
- 10 Aug 2015 Accrual to date is 62 % according to United Kingdom Clinical Research Network.